Bart Staels News Today

EQS-News: Evotec SE / Key word: Miscellaneous Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity...

CVD risk increases with the severity of nonalcoholic fatty liver disease, and both CV and liver events are “highly related” to the degree of hepatic fibrosis present, according to a speaker.CVD remains the leading cause of death in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis, Bart Staels, PhD, professor at the Faculty of Pharmacy, University of Lille, France,

Genfit (OTCMKTS:GNFTF – Get Rating) is one of 334 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Genfit to similar companies based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, valuation and institutional ownership. Earnings & Valuation This table compares Genfit and its […]

Genfit (OTCMKTS:GNFTF – Get Rating) is one of 346 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Genfit to similar companies based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, dividends and risk. Valuation and Earnings This table compares Genfit […]

Genfit (NASDAQ:GNFT – Get Rating) and Aura Biosciences (NASDAQ:AURA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Analyst Ratings This is a summary of current ratings for […]

Genfit (NASDAQ:GNFT – Get Rating) and Opthea (NASDAQ:OPT – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends. Insider and Institutional Ownership 4.5% of Genfit shares are owned by […]

Inhibikase Therapeutics (NYSE:IKT – Get Rating) and Genfit (NASDAQ:GNFT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Risk and Volatility Inhibikase Therapeutics has a beta of 0.94, […]